Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies how well Jaktinib and azacytidine work in treating patients
with myelodysplastic syndromes with myelofibrosis or myelodysplastic
syndrome/myeloproliferative neoplasm with myelofibrosis. Giving Jaktinib and azacytidine may
be an effective treatment for myelodysplastic syndromes with myelofibrosis or myelodysplastic
syndrome/myeloproliferative neoplasm with myelofibrosis.